RU2664705C2 - Агонисты рецептора окситоцина для лечения заболеваний центральной нервной системы - Google Patents

Агонисты рецептора окситоцина для лечения заболеваний центральной нервной системы Download PDF

Info

Publication number
RU2664705C2
RU2664705C2 RU2015130950A RU2015130950A RU2664705C2 RU 2664705 C2 RU2664705 C2 RU 2664705C2 RU 2015130950 A RU2015130950 A RU 2015130950A RU 2015130950 A RU2015130950 A RU 2015130950A RU 2664705 C2 RU2664705 C2 RU 2664705C2
Authority
RU
Russia
Prior art keywords
pyrazol
benzenesulfonamide
pyridin
halogen
lower alkyl
Prior art date
Application number
RU2015130950A
Other languages
English (en)
Russian (ru)
Other versions
RU2015130950A (ru
Inventor
Катерина БИССАНЦ
Кристоф ГРУНДШОБЕР
Маттиас НЕТТЕКОФЕН
Жан-Марк ПЛАНШЕР
Вальтер ВИФИАН
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of RU2015130950A publication Critical patent/RU2015130950A/ru
Application granted granted Critical
Publication of RU2664705C2 publication Critical patent/RU2664705C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/42—Benzene-sulfonamido pyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
RU2015130950A 2013-01-17 2014-01-14 Агонисты рецептора окситоцина для лечения заболеваний центральной нервной системы RU2664705C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13151632.0 2013-01-17
EP13151632 2013-01-17
PCT/EP2014/050526 WO2014111356A1 (en) 2013-01-17 2014-01-14 Oxytocin receptor agonists for the treatment of cns diseases

Publications (2)

Publication Number Publication Date
RU2015130950A RU2015130950A (ru) 2017-02-21
RU2664705C2 true RU2664705C2 (ru) 2018-08-21

Family

ID=47559324

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015130950A RU2664705C2 (ru) 2013-01-17 2014-01-14 Агонисты рецептора окситоцина для лечения заболеваний центральной нервной системы

Country Status (10)

Country Link
US (1) US9751870B2 (enExample)
EP (1) EP2945624B1 (enExample)
JP (1) JP6263553B2 (enExample)
KR (1) KR20150108384A (enExample)
CN (1) CN104936593B (enExample)
BR (1) BR112015016323A2 (enExample)
CA (1) CA2898015A1 (enExample)
MX (1) MX2015008830A (enExample)
RU (1) RU2664705C2 (enExample)
WO (1) WO2014111356A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
RS65144B1 (sr) * 2014-09-19 2024-02-29 Ferring Bv Postupak za lečenje prader-vilijevog sindroma
EP3852724A4 (en) 2018-09-20 2022-07-06 Levo Therapeutics, Inc. CARBETOCIN DRUG PRODUCT AND PROCESS FOR ITS MANUFACTURE
US20200093884A1 (en) 2018-09-20 2020-03-26 Mark C. Manning Stable intranasal formulations of carbetocin
EP3934636A1 (en) * 2019-03-06 2022-01-12 Institut National de la Santé et de la Recherche Médicale (INSERM) Inhibitors of ngal protein
WO2022200568A1 (en) 2021-03-26 2022-09-29 Ot4B Treatment of dysphagia
CN116459261A (zh) * 2023-02-27 2023-07-21 徐州医科大学 Lit-001在治疗焦虑疾病中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB865341A (en) * 1958-07-30 1961-04-12 Bayer Ag 5-benzene-sulphonamido-1-phenyl pyrazole derivatives
GB893755A (en) * 1958-06-25 1962-04-11 Ciba Ltd New pyrazoles and process for their manufacture
GB1054278A (en) * 1963-11-05 1967-01-11 Ciba Ltd. Pharmaceutical preparations having hypoglycaemic properties
RU2366657C2 (ru) * 2004-01-12 2009-09-10 Санофи-Авентис Производные n-(1,5-дифенил-1н-пиразол-3-ил)сульфонамида со сродством к рецепторам cb1
EP2221298A1 (en) * 2007-11-13 2010-08-25 Taisho Pharmaceutical Co., Ltd Phenylpyrazole derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3014038A (en) * 1961-12-19 Xnhxs
DE1115739B (de) 1958-06-25 1961-10-26 Ciba Geigy Verfahren zur Herstellung von 1-Phenyl-5-(benzolsulfonamido)-pyrazolen
DE1115261B (de) * 1958-07-30 1961-10-19 Bayer Ag Verfahren zur Herstellung von 1-Phenyl-5-(benzolsulfonamido)-pyrazolen
US6531478B2 (en) * 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
JP5756457B2 (ja) * 2009-04-06 2015-07-29 アジオス ファーマシューティカルズ， インコーポレイテッド ピルビン酸キナーゼｍ２調節剤、治療組成物および関連する使用方法
WO2012016229A2 (en) 2010-07-30 2012-02-02 The Regents Of The University Of California Oxytocin treatment to improve memory and modify blood glucose

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB893755A (en) * 1958-06-25 1962-04-11 Ciba Ltd New pyrazoles and process for their manufacture
GB865341A (en) * 1958-07-30 1961-04-12 Bayer Ag 5-benzene-sulphonamido-1-phenyl pyrazole derivatives
GB1054278A (en) * 1963-11-05 1967-01-11 Ciba Ltd. Pharmaceutical preparations having hypoglycaemic properties
RU2366657C2 (ru) * 2004-01-12 2009-09-10 Санофи-Авентис Производные n-(1,5-дифенил-1н-пиразол-3-ил)сульфонамида со сродством к рецепторам cb1
EP2221298A1 (en) * 2007-11-13 2010-08-25 Taisho Pharmaceutical Co., Ltd Phenylpyrazole derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
RING RH et al. Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology 2010 Jan; 58(1): 69-77, [он лайн] [найдено 09.11.2017] (найдено из интернет: www.ncbi.nlm.nih.gov/pubmed/19615387). *
RING RH et al. Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology 2010 Jan; 58(1): 69-77, реферат [он лайн] [найдено 09.11.2017] (найдено из интернет: www.ncbi.nlm.nih.gov/pubmed/19615387). *
ROSSATO G. et al. Probing small-molecule binding to cytochrome P450 2D6 and 2C9: an in silico protocol for generating toxicity alerts. ChemMedChem. 2010 Dec. 3; 5(12): 2088-101 [он лайн] [найдено 09.11.2017] (найдено из интернет: www.ncbi.nlm.nih.gov/pubmed/21038340) c. 2097, , табл. 3. *
ROSSATO G. et al. Probing small-molecule binding to cytochrome P450 2D6 and 2C9: an in silico protocol for generating toxicity alerts. ChemMedChem. 2010 Dec. 3; 5(12): 2088-101 [он лайн] [найдено 09.11.2017] (найдено из интернет: www.ncbi.nlm.nih.gov/pubmed/21038340) c. 2097, реферат, табл. 3. *

Also Published As

Publication number Publication date
JP2016506910A (ja) 2016-03-07
EP2945624A1 (en) 2015-11-25
US9751870B2 (en) 2017-09-05
BR112015016323A2 (pt) 2017-07-11
CA2898015A1 (en) 2014-07-24
JP6263553B2 (ja) 2018-01-17
KR20150108384A (ko) 2015-09-25
CN104936593A (zh) 2015-09-23
WO2014111356A1 (en) 2014-07-24
CN104936593B (zh) 2018-05-18
US20150322058A1 (en) 2015-11-12
RU2015130950A (ru) 2017-02-21
EP2945624B1 (en) 2018-04-18
HK1209032A1 (en) 2016-03-24
MX2015008830A (es) 2015-10-14

Similar Documents

Publication Publication Date Title
JP6263553B2 (ja) Ｃｎｓ疾患の処置のためのオキシトシン受容体アゴニスト
JP7266538B2 (ja) Ｆｘｒ受容体作動薬としてのラクタム系化合物
RU2479577C2 (ru) Гетероциклические соединения в качестве положительных модуляторов метаботропного глутаматного рецептора 2 (рецептора mglu2)
CA3133753A1 (en) Novel small molecule inhibitors of tead transcription factors
RU2752173C2 (ru) Пиразоловые соединения в качестве модуляторов fshr и пути их применения
TW201742863A (zh) 靶向蛋白質之嵌合化合物、組合物、方法及其用途
EP2089367B1 (en) Pyrazoline compounds as mineralocorticoid receptor antagonists
DK3194403T3 (en) PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS
ES2369714T3 (es) Pirazina sulfonamidas 2,3 sustituidas como inhibidores de crth2.
KR20180134998A (ko) 아실 술폰아미드 NaV1.7 억제제
CN115745891A (zh) 吡唑衍生物在作为β2-肾上腺素受体别构拮抗剂的应用
JP2025518207A (ja) ピリジン－ｎ－オキシド化合物の調製方法
WO2026041142A1 (zh) 作为vav1降解剂的化合物及其用途
EP3891130B1 (en) Ire1 small molecule inhibitors
WO2021127459A1 (en) Gpr139 receptor modulators
JP2008509962A (ja) ５−ｈｔ７受容体アンタゴニスト
WO2023280290A1 (zh) 一种吡咯磺酰类衍生物、及其制备方法与应用
WO2021228215A1 (zh) 可用作RORγ调节剂的联芳基类化合物
JP2024546943A (ja) Ｒｘｆｐ１アゴニストとしてのテトラリン、フェニルシクロブタン、およびフェニルシクロペンタン類似体
JP4773335B2 (ja) オキシトシンアンタゴニストとしてのピロリジン誘導体
HK1209032B (en) Oxytocin receptor agonists for the treatment of cns diseases
WO2015054038A1 (en) Cathepsin cysteine protease inhibitors
CN106317059A (zh) 一种新的大麻素受体2（cb2）激动剂
KR20050100695A (ko) ２-아미노에틸 치환된 피리미딘-２-온, 사이클로프로판,피라졸린, 피리미딘 및 벤조티아제핀, 및 이들의 유로텐신ⅱ 및 소마토스타틴 ５ 리셉터의 리간드로서의 용도
EA038294B1 (ru) Гетероциклические соединения, применимые в лечении заболеваний

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200115